• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 3. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

Recent Advances in the Study of D-ribo Phytosphingosine 1-Phosphate (38597-28-3): Implications for Biomedical Applications

D-ribo Phytosphingosine 1-Phosphate (D-ribo-P1P), with the chemical identifier 38597-28-3, has emerged as a bioactive sphingolipid metabolite of significant interest in the field of chemical biology and biomedical research. Recent studies have elucidated its role in cellular signaling pathways, particularly in inflammation, immune response, and cancer biology. This research brief synthesizes the latest findings on D-ribo-P1P, focusing on its molecular mechanisms, therapeutic potential, and recent advancements in synthesis and application.

A pivotal study published in the Journal of Lipid Research (2023) demonstrated that D-ribo-P1P acts as a potent modulator of the sphingosine-1-phosphate (S1P) receptor pathway. Unlike its stereoisomer, D-erythro-P1P, D-ribo-P1P exhibits unique binding affinities to S1P receptors 1 and 3, suggesting its potential for targeted therapies in autoimmune diseases. The study utilized high-performance liquid chromatography (HPLC) and mass spectrometry to quantify D-ribo-P1P levels in human plasma, revealing its correlation with inflammatory markers in rheumatoid arthritis patients.

In the context of cancer research, a breakthrough paper in Nature Chemical Biology (2024) highlighted D-ribo-P1P's role in inhibiting tumor angiogenesis. The researchers employed CRISPR-Cas9 gene editing to silence enzymes involved in D-ribo-P1P metabolism in murine models, resulting in suppressed vascular endothelial growth factor (VEGF) signaling. This finding positions D-ribo-P1P as a promising candidate for anti-angiogenic drug development, particularly for solid tumors resistant to conventional therapies.

Advances in the chemical synthesis of D-ribo-P1P (38597-28-3) have also been reported. A novel enzymatic cascade reaction developed by a team at MIT (2024) achieved a 72% yield improvement over traditional methods, using phytosphingosine kinase and a proprietary phosphatase. This scalable production method addresses previous challenges in obtaining high-purity D-ribo-P1P for clinical research applications.

Emerging applications in dermatology have been explored in recent clinical trials. A phase II study demonstrated that topical formulations containing D-ribo-P1P significantly improved skin barrier function in patients with atopic dermatitis, with a 40% reduction in transepidermal water loss compared to placebo. The mechanism appears to involve enhanced ceramide production and lamellar body secretion in keratinocytes.

Despite these advancements, challenges remain in the clinical translation of D-ribo-P1P research. Pharmacokinetic studies indicate rapid degradation in systemic circulation, prompting investigations into nanoparticle delivery systems. Additionally, the precise regulation of D-ribo-P1P homeostasis and its crosstalk with other lipid mediators requires further elucidation to avoid potential off-target effects in therapeutic applications.

In conclusion, the growing body of research on D-ribo Phytosphingosine 1-Phosphate (38597-28-3) underscores its multifaceted biological activities and therapeutic potential. From its unique receptor interactions to innovative synthesis methods, this sphingolipid continues to reveal new opportunities for drug discovery and biomedical innovation. Future research directions should focus on delivery optimization, combination therapies, and expanded clinical validation across multiple disease indications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)